2. Protein Tyrosine Kinase/RTK Apoptosis
  3. PDGFR Apoptosis
  4. PDGFR-IN-1

PDGFR-IN-1 (compound 7m) 是一种口服有效的 PDGFR (血小板源性生长因子受体) 抑制剂, PDGFRα 和 PDGFRβ 的 IC50 分别为 2.4 和 0.9 nM。PDGFR-IN-1 具有较强的抗肿瘤作用和低毒性，可用于骨肉瘤的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

PDGFR-IN-1 Chemical Structure

PDGFR-IN-1 Chemical Structure

CAS No. : 2644673-07-2

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

PDGFR-IN-1 相关抗体

Top Publications Citing Use of Products

查看 PDGFR 亚型特异性产品:

查看所有亚型
PDGFR PDGFRβ PDGFRα

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

PDGFR-IN-1 (compound 7m) is a potent and orally active PDGFR (platelet-derived growth factor receptor) inhibitor, with IC50 values of 2.4 and 0.9 nM for PDGFRα and PDGFRβ, respectively. PDGFR-IN-1 displays robust antitumor effects and low toxicity, and can be used to study osteosarcoma[1].

IC50 & Target

IC50: 2.4 nM (PDGFRα), 0.9 nM (PDGFRβ)[1]
体外研究
(In Vitro)

PDGFR-IN-1 (compound 7m) (0-0.4 μM, 48 h) inhibits osteosarcoma cancer cells (U2OS, MG63, MNNG/HOS, and SAOS-2) proliferation and colony formation[1].
PDGFR-IN-1 (0-0.4 μM, 48 h) induces cell-cycle arrest in a dose-dependent manner[1].
PDGFR-IN-1 (0-1.6 μM, 48 h) induces MNNG/HOS and MG63 cell apoptosis in a dose-dependent manner[1].
PDGFR-IN-1 (0-0.4 μM, 15 min) inhibits the expression of α-tubulin in both MNNG/HOS and MG63 cells[1].
PDGFR-IN-1 (0-0.4 μM, 48 h) inhibits PDGFRβ phosphorylation and downstream signaling transduction (p-STAT3, p-AKT, and p-ERK)[1].
PDGFR-IN-1 (0-0.4 μM, 48 h) significantly inhibits osteosarcoma cancer cell migration and invasion by downregulating the expression of FAK, as well as the distribution in the leading edge of cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PDGFR-IN-1 相关抗体:

Cell Proliferation Assay

Cell Line: Human osteosarcoma cancer cell lines (U2OS, MG63, MNNG/HOS, and SAOS-2)[1]
Concentration: 0.1, 0.2, and 0.4 μM.
Incubation Time: 48 h
Result: Showed strong antiproliferative activity against MG63, U2OS, MNNG/HOS, and SAOS-2, with IC50 values of 0.44, 0.42, 1.03, and 0.37 μM, respectively. Showed dose-dependent inhibition colony formation.

Cell Cycle Analysis

Cell Line: MG63 and MNNG/HOS cells[1]
Concentration: 0, 0.1, 0.2, 0.4 μM
Incubation Time: 48 h
Result: Induced G2/M cell-cycle arrest in MNNG/HOS and G0/G1 cell-cycle arrest in MG63 cells in a dose-dependent manner.

Apoptosis Analysis

Cell Line: MG63 and MNNG/HOS cells[1]
Concentration: 0, 0.4, 0.8, 1.6 μM
Incubation Time: 48 h
Result: Induced MNNG/HOS and MG63 cell apoptosis in a dose-dependent manner.

Immunofluorescence

Cell Line: MG63 and MNNG/HOS[1]
Concentration: 0, 0.1, 0.2, 0.4 μM
Incubation Time: 15 min
Result: Inhibited the expression of α-tubulin in both MNNG/HOS and MG63 cells, inhibited proliferation and reduced the PDGFRβ fluorescence intensity in a concentration-dependent manner.

Western Blot Analysis

Cell Line: MG63 and MNNG/HOS[1]
Concentration: 0, 0.1, 0.2, 0.4 μM
Incubation Time: 48 h
Result: Effective inhibited PDGFRβ phosphorylation and downstream signaling transduction (p-STAT3, p-AKT, and p-ERK) at the cellular level.
体内研究
(In Vivo)

PDGFR-IN-1 (BALB/c mice, MNNG/HOS xenograft mouse, 15, 30 mg/kg, orally, daily for 14 days) significantly suppresses tumor growth, exhibits a stronger antitumor efficacy with low toxicity[1].
PDGFR-IN-1 (C57/BL6 mice, 40, 80 mg/kg, orally, daily for 10 days) is safe for in vivo investigations[1].
PDGFR-IN-1 (Sprague-Dawley rats, 20 mg/kg PO or 4 mg/kg IP, once) shows a favorable profile with a high maximum concentration and exposure, an acceptable half-life , and a good oral bioavailability[1].
Pharmacokinetic Parameters of PDGFR-IN-1 in male Sprague-Dawley rats[1].

7m
route IP PO
dose (mg/kg) 4 20
Cmax (ng/mL) 78.3 75.2
t1/2 (h) 2.86 2.12
AUC0-∞ (ng/mL*h) 211.3 664.7
F (%) 62.9

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague-Dawley rats (male, 200-260 g, Six rats, two groups)[1]
Dosage: 20 mg/kg (PO) or 4 mg/kg (IP)
Administration: PO, IP, once (Pharmacokinetic Analysis)
Result: Showed a favorable profile with a high maximum concentration and exposure, an acceptable half-life , and a good oral bioavailability.
Animal Model: BALB/c mice (18-20 g, MNNG/HOS xenograft mouse, eight groups)[1]
Dosage: 15, 30 mg/kg
Administration: Orally, daily for 14 days
Result: Significantly suppressed tumor growth, exhibited a stronger antitumor efficacy, did not cause significant body weight or organ weight (heart, lung, liver, spleen, or kidney) changes, strongly suppressed the proliferation of tumor cells and induced apoptosis in tissues of the tumor.
Animal Model: C57/BL6 mice[1]
Dosage: 40, 80 mg/kg
Administration: Orally, daily for 10 days
Result: Did not reveal any obvious morphological aberration in organ tissues.
分子量

458.56

Formula

C25H30N8O
CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

PDGFR-IN-1 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PDGFR-IN-12644673-07-2PDGFRApoptosisPlatelet-derived growth factor receptorOsteosarcomaMG63 cellMNNG/HOS cellLow toxicityBioavailabilityMetabolic stabilityOrally activeInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
PDGFR-IN-1
目录号：
HY-144653
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z